Expression of basic fibroblast growth factor in liver cancer and chronic hepatitis B
[1]李敬兰, 赵纯平, 林治库, 等.血清层粘连蛋白、透明质酸检测在癌症及肝病的临床意义[J].中国临床综合, 2002, 18 (2) ∶126-127.
|
[2]Bauer M, Schuppan D.TGF beta1in liver fibrosis:time to change paradigms-[J].FEBS Lett, 2001, 502 (1/2) ∶1-3.
|
[3]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329.
|
[4]康海燕, 张杏, 王建彬.碱性成纤维细胞生长因子及转化生长因子β1与肝纤维化的研究[J].临床肝胆病杂志, 2007, 23 (6) ∶465-467.
|
[5]Sasada R, Kurokawa T, Iwane M, et al.Transformation of mouse BALB/c3T3cells with human basic fibroblast growth factor cDNA[J].Mol Cell Biol, 1988, 8 (2) ∶588-594.
|
[6]Ogasawara S, Yano H, Iemura A, et al.Expressions of basic fibro-blast growth factor and its receptors and their relationship to prolifera-tion of human hepatocellular carcinoma cell lines[J].Hepatology, 1996, 24 (1) ∶198-205.
|
[7]Gulubova MV, Stoyanov HD, Julianov AE, et al.Immunohistochem-ical detection of collagen typeⅢandⅣin relation with transforma-tion of Ito cells in liver sinusoids of patients with reactive biliary hep-atitis[J].Acta Histochem, 1999, 101 (2) ∶213-228.
|
[8]王泰龄, 王宝恩, 刘霞, 等.慢性病毒性肝炎纤维化分期与血清指标的关系[J].中华病理学杂志, 1998, 27 (3) ∶185-190.
|
[1] | Ziyi LI, Wanjie ZHANG, Fuchun WANG, Xiaorong MAO, Junfeng LI. Role of T lymphocytes in primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2926-2931. doi: 10.3969/j.issn.1001-5256.2023.12.026 |
[2] | Long LIU, Ke SHI, Qun ZHANG, Chongping RAN, Jie HOU, Yi ZHANG, Xianbo WANG. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(7): 1589-1593. doi: 10.3969/j.issn.1001-5256.2021.07.022 |
[3] | Yuecheng YU, Chengwei CHEN. Pathogenesis of drug-induced liver injury: Current understanding and future needs[J]. Journal of Clinical Hepatology, 2021, 37(11): 2515-2524. doi: 10.3969/j.issn.1001-5256.2021.11.003 |
[4] | Qu Yao, Zhang Wei. Role of cell apoptosis in the pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1397-1400. doi: 10.3969/j.issn.1001-5256.2019.06.049 |
[5] | Chang BinXia, Wang Hua, Zou ZhengSheng, Li BaoSen, Gao Bin. Pathogenesis and novel therapeutic targets of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2014, 30(2): 113-117. doi: 10.3969/j.issn.1001-5256.2014.02.004 |
[6] | Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155. |
[7] | Luo FangQiong, Pan Yu, Liu JingJing, Zhang Peng, Niu JunQi, Jiang YanFang. The Impact of Adefovior dipivoxil on Th1/Th2 cytokines in chronic hepatitis B Patients[J]. Journal of Clinical Hepatology, 2010, 26(1): 19-21. |
[8] | Huang ZhongFa, Zhu Qing, Fu QiMei, Bu QuanHui, Shi BinBin. The effect of Interferon treatment on cellular immuneresponses in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(5): 326-328. |
[9] | Zhao Shuang, Yan XueBing, Wang JinZhang, Hao JunGui, Wang MingShan, Feng Xia, Wan MeiRong. The study on imblance of cytotoxic T cells subtype (Tc1/Tc2) in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(6): 417-419. |
[17] | Yin HongZhu, Liu JinXing, Cao ZhiChen, Li BingShun, Tang HuiHua, Feng ZhongJun. The Study of the role of Soluble Intercellular Adhesion Molecule-1 in Patients with Chronic hepatitis B[J]. Journal of Clinical Hepatology, 2000, 16(4): 230-231. |